Pharvaris N.V. (PHVS) 股票分析

公司概述

Pharvaris N.V. operates as a late-stage biopharmaceutical enterprise dedicated to the development and commercialization of novel therapies addressing rare diseases characterized by unmet medical needs, specifically focusing on conditions mediated by bradykinin such as angioedema. The company functions within the broader healthcare sector and the specialized biotechnology industry, a domain defined by high capital expenditure requirements and a focus on innovative drug discovery rather than mature product sales. As of the latest data, the company possesses a market capitalization of $1.78B and employs a workforce of 118 individuals, reflecting a mid-sized operational scale typical of clinical-stage entities. These financial metrics, particularly the substantial market cap relative to its employee count, indicate that the market assigns significant value to the company's pipeline assets, specifically its lead candidate deucrictibant, a small molecule bradykinin B2-receptor antagonist, despite the current lack of revenue generation.

财务健康

Pharvaris N.V. reports a Net Income (TTM) of $-163,719,488 and an EBITDA of $-167,259,872, while annual revenue is listed as N/A, a status common for companies in the pre-revenue or early commercialization phases. The absence of recorded revenue against such large negative net income highlights a cost structure dominated by research, development, and operational expenses necessary to advance therapies through clinical trials. The company maintains a Free Cash Flow of $-76,153,248, which signifies that current cash reserves are being consumed to fund ongoing operations and product development rather than generating liquidity for shareholders. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting that the company has not yet achieved commercial profitability to establish meaningful margins on sales. On the balance sheet, the company holds $329.29M in cash against total debt of $578,657, resulting in a Debt to Equity ratio of 0.18, which suggests a conservative leverage profile with minimal financial obligations relative to equity. The Current Ratio stands at 12.86, indicating an extremely robust short-term liquidity position where current assets vastly exceed current liabilities, providing ample buffer for immediate obligations. Furthermore, the Return on Equity is -53.8% and the Return on Assets is -32.1%, metrics that reveal that management is currently deploying capital to generate losses rather than returns, a typical characteristic of high-growth biotechnology firms investing heavily in future potential.

估值评估

The company's valuation metrics present a complex picture due to the lack of earnings, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -8.59, implying that future earnings projections are negative or that the denominator in the valuation formula results in a negative multiple. The Price to Book ratio is 4.93, suggesting that the market values the company's equity at nearly five times its book value, a premium often attributed to the intangible value of the intellectual property and pipeline rather than tangible assets. Alternative valuation measures such as the Price to Sales ratio (N/A) and EV/EBITDA (-8.66) further complicate traditional assessment, with the negative EV/EBITDA reinforcing the fact that the enterprise value exceeds the book value in a loss-making scenario. In terms of trading range, the 52-Week High is $29.80 and the 52-Week Low is $11.51; without a specific current price provided in the source data, the valuation context relies on these historical bounds to gauge volatility. The Beta value is -2.71, an anomalous figure for equities that typically indicates extreme inverse correlation to the broader market, suggesting that the stock price moves in a highly volatile and counter-intuitive manner relative to general market indices.

Growth & Income

Pharvaris N.V. exhibits N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), as the company has not yet reached a stage where year-over-year growth rates can be calculated based on consistent commercial sales. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company does not distribute profits to shareholders but instead retains all earnings to fund its expensive research and development activities. This reinvestment strategy is standard for biotechnology firms in the late-stage development phase, where capital is prioritized for clinical trials and regulatory approval rather than income distribution. Consequently, the overall growth and income profile of Pharvaris N.V. is characterized by a complete reliance on capital deployment for pipeline advancement with no current income generation or shareholder yield.